Skip to main content

Sight Sciences, Inc. (SGHT)

NASDAQ: SGHT · IEX Real-Time Price · USD
25.93 2.74 (11.82%)
Oct 21, 2021 12:48 PM EDT - Market open
Market Cap1.17B
Revenue (ttm)29.78M
Net Income (ttm)-37.76M
Shares Out45.06M
EPS (ttm)-0.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume157,275
Open24.44
Previous Close23.19
Day's Range24.34 - 25.98
52-Week Range21.01 - 42.57
Betan/a
AnalystsBuy
Price Target43.00 (+65.8%)
Est. Earnings DateNov 11, 2021

About SGHT

Sight Sciences' mission is to transform ophthalmology and optometry through the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases. Sight Sciences is passionate about improving patients’ lives. Our currently marketed products, the OMNI Surgical System, or OMNI, and the TearCare System, or TearCare, target two of the world’s most prevalent and underserved eye diseases, glaucoma and dry eye disease, or DED, respectively. OMNI is a handheld, single-use, therap...

IndustryMedical Devices
IPO DateJul 15, 2021
CEOPaul Badawi
Employees169
Stock ExchangeNASDAQ
Ticker SymbolSGHT
Full Company Profile

Financial Performance

In 2020, Sight Sciences's revenue was $27.64 million, an increase of 18.38% compared to the previous year's $23.35 million. Losses were -$34.69 million, 34.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Sight Sciences stock is "Buy." The 12-month stock price forecast is 43.00, which is an increase of 65.83% from the latest price.

Price Target
$43.00
(65.83% upside)
Analyst Consensus: Buy

News

Sight Sciences Announces TearCare® Clinical Data Published in Cornea

Clinical trial data being used to seek expanded indication from the FDA Clinical trial data being used to seek expanded indication from the FDA

1 day ago - GlobeNewsWire

Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

Sight Sciences Seeks Injunction Related to Hydrus® Microstent's Infringement Sight Sciences Seeks Injunction Related to Hydrus® Microstent's Infringement

1 month ago - GlobeNewsWire

Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address th...

1 month ago - GlobeNewsWire

Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday...

2 months ago - GlobeNewsWire

Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annua...

New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented New safety and efficacy data from ...

2 months ago - GlobeNewsWire

Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase...

MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the ...

3 months ago - GlobeNewsWire

Sight Sciences Announces Pricing of Initial Public Offering

MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the ...

3 months ago - GlobeNewsWire

Sight Sciences IPO Registration Document (S-1)

Sight Sciences, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC